Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo.,...
Expands availability of Nociscan in the greater Los Angeles area Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection...
BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging...
Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as...
Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and...
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine...
Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companies Strong track record of launching breakthrough...
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back...
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89%...
Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D. underscored that...